Drug
Dotarem Enhanced Mri
Dotarem Enhanced Mri: highest development phase Post-Market, developed by Guerbet. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Guerbet
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dotarem®-enhanced MRI NCT00650845 | Post-Market | Renal Insufficiency |
Latest
No recent events.
Follow Dotarem Enhanced Mri on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.